Webcast Alert: Isis Pharmaceuticals Announces a Business Update Conference Call

CARLSBAD, Calif., July 1 /PRNewswire-FirstCall/ -- Isis
Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:



What: Isis Pharmaceuticals' business update

When: Tuesday, July 1, 2008, at 10:00 a.m. ET / 7:00 a.m. PT
Via internet: Simply log onto our web site http://www.isispharm.com and
click on the webcast icon on our home page.

Via telephone: In the United States, call 1-877-548-7901 five to ten
minutes prior to the call. You will be asked to provide your name and
indicate that you wish to participate in Isis Pharmaceuticals' conference
call hosted by Dr. Stanley Crooke.



Contacts: Kristina Lemonidis
Associate Director, Investor Relations
(760) 603-2490

Amy Blackley, Ph.D.
Manager, Corporate Communications
(760) 603-2772

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel
drugs for its product pipeline and for its partners. The Company has
successfully commercialized the world's first antisense drug and has 18
drugs in development. Isis' drug development programs are focused on
treating cardiovascular and metabolic diseases. Isis' partners are
developing antisense drugs invented by Isis to treat a wide variety of
diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is
developing and commercializing the Ibis T5000(TM) Biosensor System, a
revolutionary system to identify infectious organisms. Isis is a joint
owner of Regulus Therapeutics LLC, a joint venture focused on the
discovery, development and commercialization of microRNA therapeutics. As
an innovator in RNA-based drug discovery and development, Isis is the owner
or exclusive licensee of over 1,500 issued patents worldwide. Additional
information about Isis is available at http://www.isispharm.com.

ABOUT IBIS T5000 BIOSENSOR SYSTEM AND IBIS BIOSCIENCES, INC.

Ibis Biosciences, Inc., a majority-owned subsidiary of Isis
Pharmaceuticals, has developed and is commercializing the Ibis T5000(TM)
Biosensor System for rapid identification and characterization of
infectious agents. The Ibis T5000 is currently intended for research use
only and not for use in diagnostic procedures. It is capable of identifying
virtually all bacteria, viruses and fungi, and can provide information
about drug resistance, virulence and strain type of these pathogens.
Commercial applications for the Ibis T5000 Biosensor System include
epidemiologic surveillance, monitoring of pandemic diseases, identification
of emerging or previously unknown pathogens, forensic characterization of
human samples, identification of sources of hospital-associated infections,
and, in the future, human infectious disease diagnostics. Ibis develops,
manufactures and markets Ibis T5000 instruments and assay kits. Additional
information about Ibis can be found by selecting the Ibis link from Isis'
homepage at http://www.isispharm.com.

See Also:

• ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)



• Many Health Savings Account Owners Make IRA Transfer



• Just Out - The Future of Health and Nutrition Thru DNA Testing...



• Vegetarian Diet and Its Advantages on Health



• New Prescription Drug Card Offers Savings to Assist Chicago Area's 1.3 Million Uninsured

[Via Healthcare]